The Government is committed to supporting the growth of technologies that support non-animal research. UK Research & Innovation funds the development of techniques that replace, reduce and refine the use of animals in research (the 3Rs) through the National Centre for 3Rs (NC3Rs). Since it was established the NC3Rs has invested £89.3 million in research and £27 million in contracts through its CRACK IT Challenges scheme. UK law requires that animals are only used in science where there are no alternatives, where the number of animals used, and potential harm is the minimum needed to achieve scientific benefit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4874", "label" : {"_value" : "Biography information for Andrew Griffith"} } , "answeringMemberConstituency" : {"_value" : "Arundel and South Downs"} , "answeringMemberPrinted" : {"_value" : "Andrew Griffith"} , "dateOfAnswer" : {"_value" : "2024-01-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-19T11:09:55.977Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "216"} , "answeringDeptShortName" : {"_value" : "Science, Innovation and Technology"} , "answeringDeptSortName" : {"_value" : "Science, Innovation and Technology"} , "date" : {"_value" : "2024-01-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Animal Experiments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to help facilitate an increase in non-animal testing methods.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "9225"} , {"_about" : "http://data.parliament.uk/resources/1681596", "AnsweringBody" : [{"_value" : "Department for Science, Innovation and Technology"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1681596/answer", "answerText" : {"_value" : "
The Government is committed to supporting the growth of technologies that support non-animal research. UK Research & Innovation funds the development of techniques that replace, reduce and refine the use of animals in research (the 3Rs) through the National Centre for 3Rs (NC3Rs). Since it was established the NC3Rs has invested £89.3 million in research and £27 million in contracts through its CRACK IT Challenges scheme.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4874", "label" : {"_value" : "Biography information for Andrew Griffith"} } , "answeringMemberConstituency" : {"_value" : "Arundel and South Downs"} , "answeringMemberPrinted" : {"_value" : "Andrew Griffith"} , "dateOfAnswer" : {"_value" : "2024-01-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-19T11:07:31.99Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "216"} , "answeringDeptShortName" : {"_value" : "Science, Innovation and Technology"} , "answeringDeptSortName" : {"_value" : "Science, Innovation and Technology"} , "date" : {"_value" : "2024-01-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Animal Experiments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Science, Innovation and Technology, if her Department will take steps to create (a) partnerships and (b) collaborations with industry stakeholders to (i) establish best practice for and (ii) increase the uptake of non-animal testing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "9226"} , {"_about" : "http://data.parliament.uk/resources/1681597", "AnsweringBody" : [{"_value" : "Department for Science, Innovation and Technology"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1681597/answer", "answerText" : {"_value" : "
The Government has no current plans to establish a cross-departmental roadmap. The Government supports advances in biomedical science to reduce the use of animals in research, including stem cell research, cell culture, imaging and computer modelling techniques. UK Research & Innovation funds the development of techniques that replace, reduce and refine the use of animals in research (the 3Rs) through the National Centre for 3Rs (NC3Rs). UK law requires that animals are only used in science where there are no alternatives, where the number of animals used, and potential harm is the minimum needed to achieve scientific benefit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4874", "label" : {"_value" : "Biography information for Andrew Griffith"} } , "answeringMemberConstituency" : {"_value" : "Arundel and South Downs"} , "answeringMemberPrinted" : {"_value" : "Andrew Griffith"} , "dateOfAnswer" : {"_value" : "2024-01-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-19T11:04:29.273Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "216"} , "answeringDeptShortName" : {"_value" : "Science, Innovation and Technology"} , "answeringDeptSortName" : {"_value" : "Science, Innovation and Technology"} , "date" : {"_value" : "2024-01-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Animal Experiments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Science, Innovation and Technology, if she will have discussions with Cabinet colleagues on the potential merits of establishing a cross-departmental roadmap to transition away from animal testing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "9227"} , {"_about" : "http://data.parliament.uk/resources/1679527", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1679527/answer", "answerText" : {"_value" : "
In September 2023, NHS England published a framework for action on digital inclusion to help the system design and implement inclusive digital approaches and technologies, including actions to build digital skills and capability among patients and National Health Service staff. This covers all NHS digital platforms. Patients unable to use digital channels will continue to be able to access services via telephone and through face-to-face services.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-01-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-15T14:44:37.843Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-01-05", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Patient Choice Schemes"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to her Department's guidance entitled Elective recovery taskforce: implementation plan, published on 4 August 2023, what steps she is taking to ensure equity of access for those unable to use digital platforms.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "7964"} , {"_about" : "http://data.parliament.uk/resources/1679532", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1679532/answer", "answerText" : {"_value" : "
The department\u2019s ambition is for all children and young people, no matter what their Special Educational Need (SEN), to receive the right support to succeed in their education and as they move into adult life. The department wants them to achieve well in early years, at school (whether mainstream or special), in further education and to live more fulfilling and independent adult lives with improved employment outcomes. The department is creating a new single national SEN and disability system in England for how needs are identified and met across education, health and care, including for those with cerebral palsy.<\/p>
The department does not hold the data requested.<\/p>
The department collects data from schools in England on pupils with SEN, but type of need is held according to the categories specified in the school census.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4761", "label" : {"_value" : "Biography information for David Johnston"} } , "answeringMemberConstituency" : {"_value" : "Wantage"} , "answeringMemberPrinted" : {"_value" : "David Johnston"} , "dateOfAnswer" : {"_value" : "2024-01-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "7967"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-15T17:04:49.263Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2024-01-05", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Special Educational Needs: Cerebral Palsy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Education, how many children with cerebral palsy in (a) Bootle constituency and (b) England and Wales have been assigned education, health and care plans.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "7965"} , {"_about" : "http://data.parliament.uk/resources/1679533", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1679533/answer", "answerText" : {"_value" : "
The department wants all children and young people to be able to reach their full potential and receive the right support to succeed in their education and as they move into adult life.<\/p>
The Special Education Needs and Disability (SEND) and Alternative Provision Improvement Plan is designed to support all children, rather than being restricted to specific conditions, and to meet those needs within a fair and financially sustainable system, by improving national consistency. This will mean that the right support is provided in the right place at the right time for children and young people with SEND.<\/p>
Under the Children and Families Act 2014, mainstream schools and colleges must use their best endeavours to make sure any child or young person who has Special Educational Needs, including those with cerebral palsy and physical disabilities, gets the special educational provision they need. Alongside this, all schools have duties under the Equality Act 2010 towards individual disabled children and young people. They must make reasonable adjustments, including the provision of auxiliary aids and services for disabled children, to prevent them being put at a substantial disadvantage.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4761", "label" : {"_value" : "Biography information for David Johnston"} } , "answeringMemberConstituency" : {"_value" : "Wantage"} , "answeringMemberPrinted" : {"_value" : "David Johnston"} , "dateOfAnswer" : {"_value" : "2024-01-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-15T17:12:31.687Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2024-01-05", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Special Educational Needs: Cerebral Palsy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Education, for what reason the SEND and alternative provision improvement plan does not make specific reference to (a) cerebral palsy and (b) physical disability; and what steps her Department is taking to ensure that children with cerebral palsy are not overlooked by the SEND and alternative provision implementation board.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "7966"} , {"_about" : "http://data.parliament.uk/resources/1679534", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1679534/answer", "answerText" : {"_value" : "
The department\u2019s ambition is for all children and young people, no matter what their Special Educational Need (SEN), to receive the right support to succeed in their education and as they move into adult life. The department wants them to achieve well in early years, at school (whether mainstream or special), in further education and to live more fulfilling and independent adult lives with improved employment outcomes. The department is creating a new single national SEN and disability system in England for how needs are identified and met across education, health and care, including for those with cerebral palsy.<\/p>
The department does not hold the data requested.<\/p>
The department collects data from schools in England on pupils with SEN, but type of need is held according to the categories specified in the school census.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4761", "label" : {"_value" : "Biography information for David Johnston"} } , "answeringMemberConstituency" : {"_value" : "Wantage"} , "answeringMemberPrinted" : {"_value" : "David Johnston"} , "dateOfAnswer" : {"_value" : "2024-01-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "7965"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-01-15T17:04:49.31Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2024-01-05", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pupils: Cerebral Palsy"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Education, how many and what proportion of children with cerebral palsy attend mainstream schools.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "7967"} , {"_about" : "http://data.parliament.uk/resources/1677260", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1677260/answer", "answerText" : {"_value" : "
As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England\u2019s data questionnaire in 2018/19.<\/p>
During GIRFT\u2019s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.<\/p>
GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT\u2019s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.<\/p>
There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery & Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.<\/p>
In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.<\/p>
It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-12-18", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "6511"} , {"_value" : "6512"} , {"_value" : "6513"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-12-18T17:11:22.813Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-12-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Skin Diseases: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she is taking steps to monitor the effectiveness of NHS England\u2019s guidance on Referral optimisation for people with skin conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "6510"} , {"_about" : "http://data.parliament.uk/resources/1677261", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1677261/answer", "answerText" : {"_value" : "
As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England\u2019s data questionnaire in 2018/19.<\/p>
During GIRFT\u2019s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.<\/p>
GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT\u2019s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.<\/p>
There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery & Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.<\/p>
In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.<\/p>
It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-12-18", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "6510"} , {"_value" : "6512"} , {"_value" : "6513"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-12-18T17:11:22.877Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-12-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Skin Diseases: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if her Department will set a target for the number of trusts to adopt the NHS England guidance on Referral optimisation for people with skin conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "6511"} , {"_about" : "http://data.parliament.uk/resources/1677262", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1677262/answer", "answerText" : {"_value" : "
As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England\u2019s data questionnaire in 2018/19.<\/p>
During GIRFT\u2019s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.<\/p>
GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT\u2019s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.<\/p>
There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery & Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.<\/p>
In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.<\/p>
It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-12-18", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "6510"} , {"_value" : "6511"} , {"_value" : "6513"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-12-18T17:11:22.937Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-12-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Skin Diseases: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to page 85 of the Getting it Right First Time report on Dermatology, published by the NHS in August 2021, how many and what proportion of trusts are required to wait for commissioner approval before prescribing (a) NICE-approved biologics for psoriasis and (b) other NICE-approved drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4397", "label" : {"_value" : "Biography information for Peter Dowd"} } , "tablingMemberConstituency" : {"_value" : "Bootle"} , "tablingMemberPrinted" : [{"_value" : "Peter Dowd"} ], "uin" : "6512"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Peter+Dowd&_page=1&max-AnswerDate=2024-01-15&tablingMemberConstituency=Bootle", "page" : 0, "startIndex" : 1, "totalResults" : 1006, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }